Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares were up 11.3% during trading on Friday . The stock traded as high as $5.88 and last traded at $5.82. Approximately 835,554 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 3,190,749 shares. The stock had previously closed at $5.23.
Analysts Set New Price Targets
Several analysts have commented on RXRX shares. Needham & Company LLC restated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, September 5th. KeyCorp lifted their price objective on Recursion Pharmaceuticals from $12.00 to $15.00 in a report on Thursday, July 13th.
Recursion Pharmaceuticals Price Performance
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). Recursion Pharmaceuticals had a negative return on equity of 58.66% and a negative net margin of 520.11%. The business had revenue of $11.02 million during the quarter, compared to analyst estimates of $10.43 million. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.47 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 37,177 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $5.20, for a total value of $193,320.40. Following the transaction, the chief executive officer now directly owns 836,820 shares of the company’s stock, valued at approximately $4,351,464. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Christopher Gibson sold 37,177 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $5.20, for a total transaction of $193,320.40. Following the completion of the sale, the chief executive officer now owns 836,820 shares in the company, valued at approximately $4,351,464. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Secora sold 25,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $8.90, for a total value of $222,500.00. Following the sale, the chief financial officer now owns 863,186 shares of the company’s stock, valued at approximately $7,682,355.40. The disclosure for this sale can be found here. Insiders have sold a total of 339,816 shares of company stock valued at $2,639,117 in the last three months. Insiders own 19.96% of the company’s stock.
Institutional Trading of Recursion Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in RXRX. Norges Bank bought a new stake in Recursion Pharmaceuticals during the 4th quarter valued at approximately $33,703,000. Kinnevik AB publ boosted its stake in Recursion Pharmaceuticals by 36.0% during the 2nd quarter. Kinnevik AB publ now owns 10,405,668 shares of the company’s stock valued at $77,730,000 after purchasing an additional 2,752,607 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals by 320.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,523,124 shares of the company’s stock valued at $26,952,000 after purchasing an additional 2,685,724 shares during the period. State Street Corp lifted its position in shares of Recursion Pharmaceuticals by 114.3% in the 3rd quarter. State Street Corp now owns 4,555,759 shares of the company’s stock worth $48,473,000 after acquiring an additional 2,430,027 shares during the period. Finally, ARK Investment Management LLC lifted its position in shares of Recursion Pharmaceuticals by 45.1% in the 3rd quarter. ARK Investment Management LLC now owns 6,876,598 shares of the company’s stock worth $52,606,000 after acquiring an additional 2,138,081 shares during the period. Institutional investors own 57.82% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.
- Five stocks we like better than Recursion Pharmaceuticals
- 3 Small Caps With Big Return Potential
- MarketBeat Week in Review – 10/30 – 11/3
- Dividend Tax Calculator
- Shocking uranium play that hedge funds kept hidden
- How to Read Stock Charts for Beginners
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.